Estimaciones de analistas de Wall Street para AC Immune S.A. (ACIU): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 8 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 9 |
| Calificación media (1-5) | 0.89 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.22 | ||
| 2026-08-05 | $0.03 | $-0.10 | +128.7% |
| 2026-04-30 | $-0.19 | $-0.20 | +5.0% |
| 2026-03-13 | $-0.18 | $-0.19 | +5.3% |
| 2025-11-04 | $-0.20 | $-0.22 | +9.1% |
| 2025-08-05 | $-0.25 | $-0.20 | -25.0% |
| 2025-04-30 | $-0.21 | $-0.22 | +4.5% |
| 2025-03-13 | $-0.18 | $-0.21 | +14.3% |
Ratios de valoración
| Precio / Valor contable | 6.42 |
| EV / EBITDA | -5.05 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $23.2M | $20.3M | $7.2M | $110.5M | $15.4M | 0 | $3.9M | $14.8M | $27.3M | $3.6M |
| Coste de Ventas | $25.8M | $32.7M | $44.3M | $50.4M | $59.5M | 0 | 0 | $54.6M | $62.6M | 0 |
| Beneficio Bruto | -$2.6M | -$12.4M | -$37.1M | $60.0M | -$44.1M | 0 | $3.9M | -$39.8M | -$35.3M | $3.6M |
| I+D | $25.8M | $32.7M | $44.3M | $50.4M | $59.5M | $62.3M | $60.3M | $54.6M | $62.6M | $56.4M |
| Generales y Administrativos | $4.7M | $6.3M | $7.6M | $16.1M | $18.6M | $10.9M | $9.6M | $10.6M | $11.4M | $11.7M |
| Gastos Operativos | $33.7M | $42.8M | $56.7M | $15.5M | $17.2M | $79.0M | $74.8M | $13.8M | $17.1M | $72.4M |
| Beneficio Operativo | -$10.5M | -$22.5M | -$49.5M | $44.5M | -$61.3M | -$79.0M | -$70.8M | -$53.6M | -$52.4M | -$68.9M |
| EBITDA | -$6.8M | -$22.5M | -$49.7M | $45.8M | -$59.7M | -$70.0M | -$68.0M | -$51.8M | -$48.6M | -$67.8M |
| Gastos por Intereses | $256000 | $147000 | $334000 | $1.9M | $184000 | $581000 | $355000 | $176000 | $133000 | $191000 |
| Beneficio Antes de Impuestos | -$7.1M | -$26.4M | -$51.0M | $45.4M | -$61.9M | -$73.0M | -$70.7M | -$54.2M | -$50.9M | -$70.4M |
| Impuestos | 0 | $147000 | 0 | 0 | 0 | $3000 | $13000 | $10000 | $3000 | 0 |
| Beneficio Neto | -$7.1M | -$26.4M | -$51.0M | $45.4M | -$61.9M | -$73.0M | -$70.8M | -$54.2M | -$50.9M | -$70.4M |
| BPA | $-0.14 | $-0.46 | $-0.82 | $0.64 | $-0.86 | $-0.97 | $-0.85 | $-0.64 | $-0.51 | $-0.70 |
| BPA Diluido | $-0.14 | $-0.46 | $-0.82 | $0.64 | $-0.86 | $-0.97 | $-0.85 | $-0.64 | $-0.51 | $-0.70 |
| Acciones en Circulación (Diluidas) | $50.1M | $57.4M | $61.8M | $71.1M | $71.9M | $75.0M | $83.6M | $84.7M | $99.7M | $100.8M |
Precio
| Precio | $2.65 |
| Capitalización | $270M |
| Bolsa | NASDAQ |
| País | CH |
Empresas relacionadas: ALDX · AMRN · ANNX · ANRO · CLLS · CTNM · DRTS
Explorar sector: Healthcare · Biotechnology
Más secciones de ACIU: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones